JMP cites a positive view of genetics, breast cancer

By Lisa Kerner

Charlotte, N.C., Sept. 8 - The science of molecular genetics is finally being applied in the clinic, according to JMP Securities analyst Charles C. Duncan following discussions with Lindsay Harris, director of the breast cancer disease unit at Yale University Cancer Center.

Genetic assays have become more routinely used by physicians and more frequently requested by patients in the last couple of years, he said.

Although notable headway has been made in technical and commercial application of molecular genetics in breast cancer, additional tumor indications are expected, according to Duncan.

Harris confirmed that Genomic Health's Oncotype DX has set the standard for the clinical development of genetic assays.

In addition, there may be an expansion of Myriad Genetics' BRCAnalysis once physicians are guided on treatment options.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.